RU2020109544A - Связывающие агенты - Google Patents
Связывающие агенты Download PDFInfo
- Publication number
- RU2020109544A RU2020109544A RU2020109544A RU2020109544A RU2020109544A RU 2020109544 A RU2020109544 A RU 2020109544A RU 2020109544 A RU2020109544 A RU 2020109544A RU 2020109544 A RU2020109544 A RU 2020109544A RU 2020109544 A RU2020109544 A RU 2020109544A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- antigen
- lcdr1
- lcdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1713298.6 | 2017-08-18 | ||
| GBGB1713298.6A GB201713298D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
| GB1802595.7 | 2018-02-16 | ||
| GBGB1802595.7A GB201802595D0 (en) | 2018-02-16 | 2018-02-16 | Binding agents |
| GBGB1808570.4A GB201808570D0 (en) | 2018-05-24 | 2018-05-24 | Binding agents |
| GB1808570.4 | 2018-05-24 | ||
| PCT/GB2018/052347 WO2019034895A1 (en) | 2017-08-18 | 2018-08-17 | LIAISON AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020109544A true RU2020109544A (ru) | 2021-09-20 |
Family
ID=63371721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020109544A RU2020109544A (ru) | 2017-08-18 | 2018-08-17 | Связывающие агенты |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10683350B2 (https=) |
| EP (2) | EP3668897B1 (https=) |
| JP (3) | JP7256580B2 (https=) |
| KR (1) | KR102781208B1 (https=) |
| CN (1) | CN111212852A (https=) |
| AU (2) | AU2018316742B2 (https=) |
| BR (1) | BR112020003306A2 (https=) |
| CA (1) | CA3072998A1 (https=) |
| ES (1) | ES2983651T3 (https=) |
| IL (1) | IL272643A (https=) |
| MX (1) | MX2020001873A (https=) |
| RU (1) | RU2020109544A (https=) |
| SG (1) | SG11202001425TA (https=) |
| WO (1) | WO2019034895A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| PH12021553197A1 (en) | 2019-06-19 | 2022-11-07 | Lepu Biopharma Co Ltd | Anti-cd47 antibodies and uses thereof |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス，インコーポレイテッド | 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法 |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN111733162A (zh) * | 2020-07-01 | 2020-10-02 | 江苏莱森生物科技研究院有限公司 | 一种经基因修饰的cd47蛋白及其单克隆抗体和应用 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| CN112794903B (zh) * | 2021-04-14 | 2021-06-25 | 广州市雷德生物科技有限公司 | 一种特异性结合IFN-γ的抗体及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP2024527335A (ja) * | 2021-06-30 | 2024-07-24 | イノベイション バイオ カンパニー リミテッド | Ｃｄ４７に特異的なヒト化抗体およびそれを含むｃｄ４７関連疾患の予防または治療用医薬組成物 |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3251615A1 (en) | 2022-01-31 | 2023-08-03 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| KR102100388B1 (ko) * | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| EP3221358B1 (en) * | 2014-11-18 | 2021-07-21 | Janssen Pharmaceutica, N.V. | Cd47 antibodies, methods, and uses |
| MX391051B (es) * | 2014-12-30 | 2025-03-21 | Celgene Corp | Anticuerpos anti-cd47 y usos de los mismos. |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| PT3402820T (pt) * | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| CN111212852A (zh) | 2017-08-18 | 2020-05-29 | 超人肆有限公司 | 结合剂 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-08-17 CN CN201880066662.5A patent/CN111212852A/zh active Pending
- 2018-08-17 CA CA3072998A patent/CA3072998A1/en active Pending
- 2018-08-17 WO PCT/GB2018/052347 patent/WO2019034895A1/en not_active Ceased
- 2018-08-17 BR BR112020003306-5A patent/BR112020003306A2/pt unknown
- 2018-08-17 SG SG11202001425TA patent/SG11202001425TA/en unknown
- 2018-08-17 ES ES18759711T patent/ES2983651T3/es active Active
- 2018-08-17 RU RU2020109544A patent/RU2020109544A/ru unknown
- 2018-08-17 MX MX2020001873A patent/MX2020001873A/es unknown
- 2018-08-17 AU AU2018316742A patent/AU2018316742B2/en active Active
- 2018-08-17 JP JP2020530735A patent/JP7256580B2/ja active Active
- 2018-08-17 KR KR1020207007972A patent/KR102781208B1/ko active Active
- 2018-08-17 EP EP18759711.7A patent/EP3668897B1/en active Active
- 2018-08-17 EP EP24179206.8A patent/EP4435008A2/en not_active Withdrawn
-
2019
- 2019-08-19 US US16/543,884 patent/US10683350B2/en active Active
-
2020
- 2020-02-12 IL IL272643A patent/IL272643A/en unknown
- 2020-05-19 US US16/877,938 patent/US11370840B2/en active Active
-
2022
- 2022-06-24 US US17/849,101 patent/US20220332819A1/en not_active Abandoned
-
2023
- 2023-03-27 JP JP2023049983A patent/JP7564274B2/ja active Active
-
2024
- 2024-09-23 US US18/893,023 patent/US20250109202A1/en active Pending
- 2024-09-26 JP JP2024167571A patent/JP7825015B2/ja active Active
-
2025
- 2025-06-26 AU AU2025204808A patent/AU2025204808A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018316742B2 (en) | 2025-04-10 |
| MX2020001873A (es) | 2020-10-22 |
| US20200277375A1 (en) | 2020-09-03 |
| JP7825015B2 (ja) | 2026-03-05 |
| KR20200038533A (ko) | 2020-04-13 |
| EP3668897B1 (en) | 2024-06-05 |
| AU2025204808A1 (en) | 2025-07-17 |
| BR112020003306A2 (pt) | 2020-08-25 |
| CA3072998A1 (en) | 2019-02-21 |
| JP7256580B2 (ja) | 2023-04-12 |
| JP2023073339A (ja) | 2023-05-25 |
| JP2025000787A (ja) | 2025-01-07 |
| ES2983651T3 (es) | 2024-10-24 |
| SG11202001425TA (en) | 2020-03-30 |
| AU2018316742A1 (en) | 2020-03-19 |
| JP7564274B2 (ja) | 2024-10-08 |
| US10683350B2 (en) | 2020-06-16 |
| IL272643A (en) | 2020-03-31 |
| EP4435008A2 (en) | 2024-09-25 |
| EP3668897A1 (en) | 2020-06-24 |
| KR102781208B1 (ko) | 2025-03-17 |
| US11370840B2 (en) | 2022-06-28 |
| US20190375840A1 (en) | 2019-12-12 |
| WO2019034895A1 (en) | 2019-02-21 |
| US20220332819A1 (en) | 2022-10-20 |
| JP2020531048A (ja) | 2020-11-05 |
| US20250109202A1 (en) | 2025-04-03 |
| CN111212852A (zh) | 2020-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020109544A (ru) | Связывающие агенты | |
| JP2020531048A5 (https=) | ||
| JP2025000787A5 (https=) | ||
| US11649295B2 (en) | Asymmetric multispecific antibodies | |
| JP7583707B2 (ja) | 抗ｃｄ４７抗体及びその応用 | |
| JP2021513323A5 (https=) | ||
| JP2021519100A5 (https=) | ||
| Safdari et al. | Antibody humanization methods–a review and update | |
| US20180016351A1 (en) | Antibodies comprising sequences from camelidae to highly conserved targets | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2020535799A5 (https=) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| RU2012130840A (ru) | Соединения | |
| JP2020514277A5 (https=) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| RU2007132020A (ru) | Партнеры специфического связывания с ngf | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2020522280A5 (https=) | ||
| JP2021516537A5 (https=) | ||
| EP1769003A1 (en) | HIGH AFFINITY ANTI-TNF-alpha ANTIBODIES AND METHOD | |
| Fransson et al. | Human framework adaptation of a mouse anti-human IL-13 antibody | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP2021512652A5 (https=) | ||
| JP2021515544A5 (https=) | ||
| JP2019509714A5 (https=) |